Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2131)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (129)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (855)
  3. JNCI: Journal of the National Cancer Institute (492)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (140)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4676)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Efficacy of cabozantinib (cabo) vs everolimus (eve) by metastatic site and tumor burden in patients (pts) with advanced renal cell carcinoma (RCC) in the phase 3 METEOR trial
    Meeting Abstract

    Powles, T. B.; Escudier, B.; de Souza, P.; Chowdhury, S.; Pook, D.; Harmenberg, U.; Basappa, N.; Geynisman, D.; Merchan, J.; Redman, B. G.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase III trial of sunitinib (SU) vs placebo (PBO) as adjuvant treatment for high-risk renal cell carcinoma (RCC) after nephrectomy (S-TRAC)
    Meeting Abstract

    Ravaud, A.; Motzer, R. J.; Pandha, H. S.; Staehler, M.; George, D.; Pantuck, A. J.; Patel, A.; Chang, Y. H.; Escudier, B.; Donskov, F.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in high grade undifferentiated uterine sarcoma (HGUS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment
    Meeting Abstract

    Ray-Coquard, I. L.; Tos, A. P. D.; Coens, C.; Huizing, M.; Herraez, A. C.; Westermann, A. M.; Bompas, E.; Earl, H.; Hensley, M. L.; Negrouk, A.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Open label non-randomized multi-cohort pilot study of genetically engineered NY-ESO-1 specific NY-ESO-1c259 SPEAR T-cellsTM in HLA-A*02+ patients with synovial sarcoma (NCT01343043)
    Meeting Abstract

    Mackall, C.; D'Angelo, S.; Grupp, S.; Glod, J.; Druta, M.; Chow, W.; Chagin, K.; Mehler, M.; Kari, G.; Trivedi, T.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Safety of reduced infusion times for nivolumab plus ipilimumab (N + I) and nivolumab alone (N) in advanced melanoma
    Meeting Abstract

    Martin-Algarra, S.; Haanen, J. B.; Horak, C.; Bhatia, S.; Ribas, A.; Hwu, W. J.; Slingluff, C. L.; Sharfman, W. H.; Callahan, M.; Hodi, F. S.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase Ib/II open-label study of Ad-RTS-hIL-12 + veledimex gene therapy in chemotherapy-responsive locally advanced or metastatic breast cancer patients
    Meeting Abstract

    McArthur, H.; Page, D.; Proverbs-Singh, T.; Solomon, S.; Hudis, C.; Norton, L.; Patil, S.; Henrich, M.; Halpenny, D.; Erinjeri, J.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1b study of WNT inhibitor vantictumab (VAN, human monoclonal antibody) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients (pts) with previously untreated stage IV pancreatic cancer (PC)
    Meeting Abstract

    Messersmith, W.; Cohen, S.; Shahda, S.; Lenz, H. J.; Weekes, C.; Dotan, E.; Denlinger, C.; Kapoun, B. O. A.; Kapoun, A.; Zhang, C.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • EMBARK: A phase 3, randomized, efficacy and safety study of enzalutamide plus leuprolide, enzalutamide monotherapy and placebo plus leuprolide in men with high-risk nonmetastatic prostate cancer progressing after definitive therapy
    Meeting Abstract

    Miller, K.; Mulders, P.; Freedland, S. J.; Scher, H.; Shore, N.; Park, E.; Krivoshik, A.; Phung, D.; Modelska, K.; Scardino, P.
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • A phase I study evaluating DLYE5953A, an antibody-drug conjugate targeting the tumor-associated antigen lymphocyte antigen 6 complex locus E (Ly6E), in patients (pts) with solid tumors
    Meeting Abstract

    Modi, S.; Eder, J. P.; Lorusso, P.; Weekes, C.; Chandarlapaty, S.; Tolaney, S. M.; McLaughlin, J.; Camidge, D. R.; Chang, C. W.; Nazzal, D.; more...
    Annals of Oncology (2016)

    Fulltext@MSK | Save
  • Phase 1 study of the PSMA-targeted tubulysin small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC): Study update
    Meeting Abstract

    Morris, M. J.; Vogelzang, N. J.; Sartor, O.; Armour, A.; Petrylak, D.; Tolcher, A.; Ejadi, S.; Babiker, H. M.
    Annals of Oncology (2016)

    Fulltext@MSK | Save